Group 1 - The core viewpoint of the article highlights that Zhaoke Ophthalmology-B (06622) has seen a significant stock price increase, rising over 7% and currently trading at 4.27 HKD with a transaction volume of 10.87 million HKD [1] - Zhaoke Ophthalmology has entered into a distribution and supply agreement with PT Ferron Par Pharmaceuticals, a leading pharmaceutical company in Indonesia, for its core product, atropine sulfate eye drops (NVK002), aimed at slowing the progression of myopia in children and adolescents [1] - Under the agreement, Zhaoke Ophthalmology grants PT Ferron exclusive rights to import, promote, distribute, market, and sell the product in Indonesia, which includes an upfront payment and potential milestone payments based on certain achievements [1] Group 2 - Earlier this year, Zhaoke Ophthalmology's new drug application for a 0.01% dosage of atropine sulfate eye drops and a 0.02% dosage has been accepted by the National Medical Products Administration of China and is currently under review [1]

根据协议条款，兆科眼科授予PT Ferron在印度尼西亚进口、推广、分销、营销和销售该产品的独家权 利。兆科眼科将获得一笔预付款项，并可根据若干成就获得额外的里程碑付款。此外，今年稍早时候， 兆科眼科硫酸阿托品滴眼液0.01%剂量之简易新药申请，以及0.02%剂量之新药申请，已先后获得中国 国家药品监督管理局受理，目前正在审批过程中。 兆科眼科-B(06622)再涨超7%，截至发稿，涨6.48%，报4.27港元，成交额1087.63万港元。 消息面上，兆科眼科宣布，公司已与印尼领先制药公司PT Ferron Par Pharmaceuticals，就公司之核心产 品：用于减缓儿童和青少年近视进展的硫酸阿托品滴眼液(NVK002)，签订了一份针对印尼市场的分销 和供应协议。 ...

根据协议条款，兆科眼科授予PT Ferron在印度尼西亚进口、推广、分销、营销和销售该产品的独家权 利。兆科眼科将获得一笔预付款项，并可根据若干成就获得额外的里程碑付款。此外，今年稍早时候， 兆科眼科硫酸阿托品滴眼液0.01%剂量之简易新药申请，以及0.02%剂量之新药申请，已先后获得中国 国家药品监督管理局受理，目前正在审批过程中。 智通财经APP获悉，兆科眼科-B(06622)再涨超7%，截至发稿，涨6.48%，报4.27港元，成交额1087.63万 港元。 消息面上，兆科眼科宣布，公司已与印尼领先制药公司PT Ferron Par Pharmaceuticals，就公司之核心产 品：用于减缓儿童和青少年近视进展的硫酸阿托品滴眼液(NVK002)，签订了一份针对印尼市场的分销 和供应协议。 ...